ACAD
41.69
+0.02
+0.05%
AEMD
6.9
-0.1
-1.43%
APRI
1.85
+0.17
+10.12%
ARNA
4.44
-0.03
-0.67%
ATEC
1.39
+0.01
+0.72%
CNAT
5.16
-0.08
-1.53%
CRXM
0.327
-0.033
-9.2778%
CYTX
0.548
-0.003
-0.5449%
DXCM
79.36
-0.41
-0.51%
GNMK
8.91
+0.16
+1.83%
HALO
22.1
-0.4
-1.78%
ILMN
220.07
-0.61
-0.28%
INNV
0.12
0.00
0.00%
INO
7.92
-0.22
-2.70%
ISCO
0.043
-0.004
-7.527%
ISIS
56.13
-1.03
-1.80%
LGND
98.6
+1.51
+1.56%
LPTN
0.275
-0.005
-1.6446%
MBVX
2.71
+0.19
+7.54%
MEIP
1.77
+0.07
+4.12%
MNOV
4.02
+0.09
+2.29%
MRTX
31.3
-0.39
-1.23%
MSTX
0.48
-0.01
-2.04%
NBIX
47.31
-0.35
-0.73%
NUVA
47.29
-0.23
-0.48%
ONCS
6.35
-0.25
-3.79%
ONVO
3.74
+0.03
+0.81%
OREX
4.76
-0.17
-3.45%
OTIC
22.09
-0.52
-2.30%
QDEL
23.01
+0.04
+0.17%
RCPT
194.91
-1.36
-0.69%
RGLS
10.2
-0.34
-3.23%
RMD
55.31
+0.01
+0.02%
SCIE
0.016
0.00
0.00%
SPHS
0.823
+0.04
+5.149%
SRNE
16.68
-0.53
-3.08%
TROV
9.53
-0.19
-1.95%
VICL
0.7
+0.015
+2.1752%
ZGNX
12.8
-1.16
-8.31%
ACAD
41.69
+0.02
+0.05%
AEMD
6.9
-0.1
-1.43%
APRI
1.85
+0.17
+10.12%
ARNA
4.44
-0.03
-0.67%
ATEC
1.39
+0.01
+0.72%
CNAT
5.16
-0.08
-1.53%
CRXM
0.327
-0.033
-9.2778%
CYTX
0.548
-0.003
-0.5449%
DXCM
79.36
-0.41
-0.51%
GNMK
8.91
+0.16
+1.83%
HALO
22.1
-0.4
-1.78%
ILMN
220.07
-0.61
-0.28%
INNV
0.12
0.00
0.00%
INO
7.92
-0.22
-2.70%
ISCO
0.043
-0.004
-7.527%
ISIS
56.13
-1.03
-1.80%
LGND
98.6
+1.51
+1.56%
LPTN
0.275
-0.005
-1.6446%
MBVX
2.71
+0.19
+7.54%
MEIP
1.77
+0.07
+4.12%
MNOV
4.02
+0.09
+2.29%
MRTX
31.3
-0.39
-1.23%
MSTX
0.48
-0.01
-2.04%
NBIX
47.31
-0.35
-0.73%
NUVA
47.29
-0.23
-0.48%
ONCS
6.35
-0.25
-3.79%
ONVO
3.74
+0.03
+0.81%
OREX
4.76
-0.17
-3.45%
OTIC
22.09
-0.52
-2.30%
QDEL
23.01
+0.04
+0.17%
RCPT
194.91
-1.36
-0.69%
RGLS
10.2
-0.34
-3.23%
RMD
55.31
+0.01
+0.02%
SCIE
0.016
0.00
0.00%
SPHS
0.823
+0.04
+5.149%
SRNE
16.68
-0.53
-3.08%
TROV
9.53
-0.19
-1.95%
VICL
0.7
+0.015
+2.1752%
ZGNX
12.8
-1.16
-8.31%
Home » Events

Going Public Without an IPO: Examples from the Biotech Industry

Submitted by on February 14, 2011 – 6:11 pm

Valuations that made “sense” in 2000 have been reduced, forcing many “cram-down” financings that are painful for investors and management. Business models can and need to be as adept, flexible and creative as the science that drives our industry. There are alternative ways to “go public” that do not involve traditional capital infusion or reverse mergers and which can provide a short-term exit strategy for investors while allowing new technologies to flourish.

In this panel discussion, Rick Burgoon (V.P. Business Operations and Board member of Epiomed), Court Turner (Partner at Avalon Ventures) and Jack Florio (Sr VP Brinson Patrick Securities Corporation) will discuss pros and cons and methodologies of an innovative approach to fund-raising involving equity arrangements with development partners and the shortened S1 registration process. Div Gupta (Partner at at Latham & Watkins LLP) will moderate the discussion.

Date/Time Start:: 2/22/2011 6:00pm

Date/Time End:: 2/22/2011 8:00pm

Cost to Attend:

Web Address:: http://www.techcoastangels.com/event/going-public-without-ipo-examples-biotech-industry

Leave a comment!

Add your comment below, or trackback from your own site. You can also Comments Feed via RSS.

Be nice. Keep it clean. Stay on topic. No spam.

You can use these tags:

<a href="" title="" rel=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong> 

This is a Gravatar-enabled weblog. To get your own globally-recognized-avatar, please register at Gravatar.


two + = 10